Heron Therapeutics Inc ( (HRTX) ) has released its Q1 earnings. Here is a breakdown of the information Heron Therapeutics Inc presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Heron Therapeutics, Inc. is a commercial-stage biotechnology company that focuses on developing and commercializing therapeutic innovations to improve medical care, particularly in the acute care and oncology sectors.
In its first quarter of 2025, Heron Therapeutics reported a net revenue of $38.9 million and achieved a record adjusted EBITDA of $6.2 million. The company also reached a settlement with Mylan Pharmaceuticals regarding patent litigations for its products CINVANTI and APONVIE, with an agreed market entry date for generics set for June 1, 2032.
Key financial highlights include a 12.2% increase in net revenue compared to the same quarter in 2024, driven primarily by the acute care franchise, which saw an 89.4% revenue increase. The company’s lead product, ZYNRELEF, experienced a 60.4% growth. Heron also raised its adjusted EBITDA guidance for the full year 2025 to a range of $4 to $12 million.
Looking ahead, Heron Therapeutics is poised for continued growth, supported by expanded label indications for ZYNRELEF, the approval of the NOPAIN Act, and strategic partnerships. The company remains focused on strengthening its financial foundation and advancing its product portfolio.